-
-
-
-
-
-
News
-
-
Contact UsThe company focuses on the research, development, production, and sales of chemical raw materials and their formulations. All products have passed national GMP certification, and core products have successively passed official pharmaceutical regulatory certifications from multiple countries, including the EU EDQM, US FDA, Japanese PMDA, and South Korean MFDS. Following its successful listing on the Shenzhen Stock Exchange's ChiNext board on April 4, 2023, Keyuan Pharmaceutical has entered a phase of rapid development driven by both digital intelligence and capital, with its business spanning dozens of countries and regions worldwide.
R&D team
Strengthen the self-developed team, enhance independent innovation capabilities, and establish a central research institute.
Increase R&D incentive mechanisms and improve the enthusiasm of R&D personnel.
Product type
Bulk raw materials (cost advantage of new technology), follow-on products (3-5 products with a patent life of around 10 years annually, binding strategic customers), patented drugs (cooperation with innovative pharmaceutical companies, long-term benefits), and CMO (cooperation with companies with raw material needs).
Product innovation
Raw materials: Improve quality and reduce costs using new technologies (continuous flow, enzymatic catalysis, chiral catalysis, etc.).
Formulations: Enhance innovation capabilities and increase product value.
R&D model
Raw materials: A combination of outsourced R&D and independent R&D, with the proportion of independent R&D increasing from 30% to 80%.
Formulations: Primarily outsourced R&D, with a maximum of 5 collaborating institutions.
Address: No. 26, Keyuan Street, Shanghe County, Jinan City, Shandong Province
Free Service Hotline